Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Gracell Biotech to Start US Trial of Dual-Targeting CAR-T Therapy for Myeloma

publication date: Feb 3, 2023

Gracell Biotech, a Shanghai cell therapy company, was approved to start a US Phase Ib/II trial of its lead candidate in patients with relapsed/refractory multiple myeloma (RRMM). GC012F is an autologous CAR-T therapeutic candidate that targets B cell maturation antigen (BCMA) and CD19. It is produced on Gracell's proprietary FasTCAR next-day manufacturing platform. In long-term investigator-initiated studies, GC012F showed a 100% minimal residual disease (MRD) negativity rate in all RRMM patients. More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital